Vifor Pharma AG (SWX:VIFN) agreed to acquire Inositec AG from VI Partners AG and others for CHF 20 million on November 22, 2021. As per the transaction, Vifor Pharma will acquire 100% of the shares in Inositec AG for an upfront payment of CHF 20 million and be eligible for success based clinical earn-out payments in the low triple digit million range. The transaction is expected to occur in Q4 2021.
1st Jan change | Capi. | |
---|---|---|
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |